TY  - JOUR
AU  - Pavlović, Sonja
AU  - Fazlagić, Amira
AU  - Lozuk, Branko
AU  - Spasovski, Vesna
AU  - Vreća, Miša
AU  - Đukić, Nenad
AU  - Radak, Đorđe
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1068
AB  - Birgerova bolest (thromboangiitis obliterans) je neaterosklerotski inflamatorni proces koji uglavnom zahvata male i srednje arterije i vene u donjim i gornjim udovima. Okarakterisan je kao vrsta vaskulitisa. Nastanak, napredovanje i težina bolesti su povezani sa pušenjem. Birgerovu bolest karakterišu bol, pojava ishemičnih ulkusa, gangrena i rizik od amputacije, što značajno utiče na kvalitet života pacijenta. Trombolitička terapija, primena nesteroidnih antiinflamatornih lekova i vaskularno-hirurški rekonstruktivni zahvati su neki od terapijskih pristupa u lečenju Birgerove bolesti. Međutim, ovi načini lečenja nisu dovoljno efikasni. Još uvek najbolji efekat na poboljšanje bolesti ima prekid pušenja. U poslednje vreme, ćelijska terapija je ponudila sasvim nove mogućnosti lečenju Birgerove bolesti. Terapija mezenhimskim matičnim ćelijama (MMĆ) je prepoznata kao novi pristup u tkivnom inženjerstvu i regenerativnoj medicini, primenljiv u lečenju različitih ishemijski poremećaja, uključujući Birgerovu bolest. Prva terapija koja koristi MMĆ u lečenju Birgerove bolesti je odobrena u Indiji 2016. godine. U martu 2017. godine Evropska komisija je terapiju autolognim MMĆ iz adipoznog tkiva uvrstila u lekove "siročiće" za Birgerovu bolest. Ovaj novi terapijski pristup je neophodno validirati u narednim studijama u više kliničkih centara.
AB  - Buerger's disease or thromboangiitis obliterans, is a non-atherosclerotic inflammatory process which mostly involves medium and small sized arteries and veins in lower and upper extremities. It is categorized as vasculitis. The disease is known to be closely linked to smoking. Buerger's disease is a long-term debilitating condition because of the pain, the development of ulcers and gangrene, and the risk of amputation. Drugs effective on erythrocyte flexibility, agents acting on platelets, non-steroidal anti-inflammatory drugs and vascular reconstruction are among several therapeutic methods for Buerger's disease. However, the applied therapies are insufficiently effective. Still, the base of treatment is smoking cessation. Lately, cell therapy has offered us entirely new possibilities. Mesenchymal stem cell (MSC) treatment has been proposed as a novel approach for tissue engineering and regenerative medicine for various ischemic disorders, including Buerger's disease. In 2016, the first MSC based therapy has received regulatory approval for the treatment of Buerger's disease in India. In March 2017, orphan designation was granted by the European Commission for autologous adipose tissue-derived MSC for the treatment of Buerger's disease. Novel therapeutic approach needs to be validated in the upcoming studies conducted in different clinical centers.
PB  - Univerzitet u Beogradu - Medicinski fakultet, Beograd
T2  - Medicinska Istraživanja
T1  - Napredak u terapiji Birgerove bolesti mezenhimalnim stem ćelijama
T1  - Advancements in mesenchymal stem cell treatment for Buerger's disease
EP  - 46
IS  - 1
SP  - 40
VL  - 51
DO  - 10.5937/MedIst1701040P
ER  - 

@article{
author = "Pavlović, Sonja and Fazlagić, Amira and Lozuk, Branko and Spasovski, Vesna and Vreća, Miša and Đukić, Nenad and Radak, Đorđe",
year = "2017",
abstract = "Birgerova bolest (thromboangiitis obliterans) je neaterosklerotski inflamatorni proces koji uglavnom zahvata male i srednje arterije i vene u donjim i gornjim udovima. Okarakterisan je kao vrsta vaskulitisa. Nastanak, napredovanje i težina bolesti su povezani sa pušenjem. Birgerovu bolest karakterišu bol, pojava ishemičnih ulkusa, gangrena i rizik od amputacije, što značajno utiče na kvalitet života pacijenta. Trombolitička terapija, primena nesteroidnih antiinflamatornih lekova i vaskularno-hirurški rekonstruktivni zahvati su neki od terapijskih pristupa u lečenju Birgerove bolesti. Međutim, ovi načini lečenja nisu dovoljno efikasni. Još uvek najbolji efekat na poboljšanje bolesti ima prekid pušenja. U poslednje vreme, ćelijska terapija je ponudila sasvim nove mogućnosti lečenju Birgerove bolesti. Terapija mezenhimskim matičnim ćelijama (MMĆ) je prepoznata kao novi pristup u tkivnom inženjerstvu i regenerativnoj medicini, primenljiv u lečenju različitih ishemijski poremećaja, uključujući Birgerovu bolest. Prva terapija koja koristi MMĆ u lečenju Birgerove bolesti je odobrena u Indiji 2016. godine. U martu 2017. godine Evropska komisija je terapiju autolognim MMĆ iz adipoznog tkiva uvrstila u lekove "siročiće" za Birgerovu bolest. Ovaj novi terapijski pristup je neophodno validirati u narednim studijama u više kliničkih centara., Buerger's disease or thromboangiitis obliterans, is a non-atherosclerotic inflammatory process which mostly involves medium and small sized arteries and veins in lower and upper extremities. It is categorized as vasculitis. The disease is known to be closely linked to smoking. Buerger's disease is a long-term debilitating condition because of the pain, the development of ulcers and gangrene, and the risk of amputation. Drugs effective on erythrocyte flexibility, agents acting on platelets, non-steroidal anti-inflammatory drugs and vascular reconstruction are among several therapeutic methods for Buerger's disease. However, the applied therapies are insufficiently effective. Still, the base of treatment is smoking cessation. Lately, cell therapy has offered us entirely new possibilities. Mesenchymal stem cell (MSC) treatment has been proposed as a novel approach for tissue engineering and regenerative medicine for various ischemic disorders, including Buerger's disease. In 2016, the first MSC based therapy has received regulatory approval for the treatment of Buerger's disease in India. In March 2017, orphan designation was granted by the European Commission for autologous adipose tissue-derived MSC for the treatment of Buerger's disease. Novel therapeutic approach needs to be validated in the upcoming studies conducted in different clinical centers.",
publisher = "Univerzitet u Beogradu - Medicinski fakultet, Beograd",
journal = "Medicinska Istraživanja",
title = "Napredak u terapiji Birgerove bolesti mezenhimalnim stem ćelijama, Advancements in mesenchymal stem cell treatment for Buerger's disease",
pages = "46-40",
number = "1",
volume = "51",
doi = "10.5937/MedIst1701040P"
}

Pavlović, S., Fazlagić, A., Lozuk, B., Spasovski, V., Vreća, M., Đukić, N.,& Radak, Đ.. (2017). Napredak u terapiji Birgerove bolesti mezenhimalnim stem ćelijama. in Medicinska Istraživanja
Univerzitet u Beogradu - Medicinski fakultet, Beograd., 51(1), 40-46.
https://doi.org/10.5937/MedIst1701040P

Pavlović S, Fazlagić A, Lozuk B, Spasovski V, Vreća M, Đukić N, Radak Đ. Napredak u terapiji Birgerove bolesti mezenhimalnim stem ćelijama. in Medicinska Istraživanja. 2017;51(1):40-46.
doi:10.5937/MedIst1701040P .

Pavlović, Sonja, Fazlagić, Amira, Lozuk, Branko, Spasovski, Vesna, Vreća, Miša, Đukić, Nenad, Radak, Đorđe, "Napredak u terapiji Birgerove bolesti mezenhimalnim stem ćelijama" in Medicinska Istraživanja, 51, no. 1 (2017):40-46,
https://doi.org/10.5937/MedIst1701040P . .